Journal of Endocrinological Investigation

, Volume 32, Issue 9, pp 766–772 | Cite as

Dehydroepiandrosterone sulfate and cognitive function in the elderly: The InCHIANTI Study

  • G. Valenti
  • L. Ferrucci
  • F. Lauretani
  • G. Ceresini
  • S. Bandinelli
  • M. Luci
  • G. Ceda
  • M. Maggio
  • R. S. Schwartz
Original Articles


DHEA and its sulfate derivative (DHEAS) decline with age. The decline in DHEAS levels has been associated with many physiological impairments in older persons including cognitive dysfunction. However, data regarding the possible relationship between DHEAS and cognition are scant. We investigated whether DHEAS levels are associated with presence and development of lower cognitive function measured by the Mini Mental State Examination (MMSE) in older men and women. One thousand and thirty-four residents aged ≥65 yr of the InCHIANTI Study with data available on DHEAS and MMSE were randomly selected. MMSE was administered at baseline and 3 yr later. Among these, 841 completed a 3-yr follow-up. Parsimonious models obtained by backward selection from initial fully-adjusted models were used to identify independent factors associated with MMSE and DHEAS. The final analysis was performed in 755 participants (410 men and 345 women) with MMSE score ≥21. A significant age-related decline of both DHEAS levels (p<0.001) and MMSE score (p<0.001) was found over the 3-yr follow-up. At enrolment, DHEAS was significantly and positively associated with MMSE score, independently of age and other potential confounders (β±SE 0.003±0.001, p<0.005). Low baseline DHEAS levels were predictive of larger decline of MMSE and this relationship was significant after adjusting for covariates (β±SE −0.004±0.002, p<0.03). Our data show a significant and positive association between DHEAS and cognitive function, assessed by MMSE test. Low DHEAS levels predict accelerated decline in MMSE score during the 3-yr follow-up period.


Cognitive function DHEAS elderly 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. G. Marked decline in serum concentration of adrenal C 19 sex steroid precursor and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997, 82: 2396–402.PubMedCrossRefGoogle Scholar
  2. 2.
    Bjørnerem A, Straume B, Midtby M, et al. Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic disease in a general population: the Tromsø Study. J Clin Endocrinol Metab 2004, 89: 6039–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Valenti G, Denti L, Saccò M, et al; GISEG (Italian Study Group on Geriatric Endocrinology). Consensus document substitution therapy with DHEA in the elderly. Aging Clin Exp Res 2006, 18: 277–300.PubMedCrossRefGoogle Scholar
  4. 4.
    Markowski M, Ungeheuer M, Bitran D, Locurto C. Memory-enhancing effects of DHEAS in aged mice on a win-shift water escape task. Physiol Behav 2001, 72: 521–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Fedotova J, Sapronov N. Behavioral effects of dehydroepiandrosterone in adult male rats. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28: 1023–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Farr SA, Banks WA, Uezu K, Gaskin FS, Morley JE. DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice. Life Sci 2004, 75: 2775–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Sujkovic E, Mileusnic R, Fry JP, Rose SP. Temporal effects of dehydroepiandrosterone sulphate on memory formation in day-old chicks. Neuroscience 2007, 148: 375–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Fonda SJ, Bertrand R, O’Donnell A, Longcope C, McKinlay JB. Age, hormones, and cognitive functioning among middle-aged and elderly men: cross-sectional evidence from the Massachusetts Male Aging Study. J Gerontol A Biol Sci Med Sci 2005, 60: 385–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 2008, 93: 801–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Barrett-Connor E, Edelstein SL. A prospective study of dehydroepiandrosterone sulphate, and cognitive function in an older population: the Rancho Bernardo Study. J Am Geriatr Soc 1994, 42: 420–3.PubMedGoogle Scholar
  11. 11.
    Yaffe K, Ettinger B, Pressman A, et al. Neuropsychiatric and dehydropeiandrosterone sulphate in elderly women: a prospective study. Biol Psychiatry 1998, 43: 694–700.PubMedCrossRefGoogle Scholar
  12. 12.
    Moffat SD, Zonderman AB, Harman SM, et al. The relationship between longitudinal declines in dehydroepiandrosterone sulphate concentrations and cognitive performance in older men. Arch Inter Med 2000, 160: 2193–8.CrossRefGoogle Scholar
  13. 13.
    Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationship of dehydroepiandrosterone sulphate in the elderly with functional, physiological and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci U S A 1996, 93: 13410–5.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kalmijn S, Launer LJ, Stolk RP, et al. A prospective study on cortisol, dehydroepiandrosterone sulphate, and cognitive function in the elderly. J Clin Endocrinol Metab 1998, 83: 3487–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997, 82: 2363–7.PubMedGoogle Scholar
  16. 16.
    Wolf OT, Naumann E, Hellhammer DH, Kirschbaum C. Effects of dehydroepiandrosterone replacement in elderly men on event-related potentials, memory and well-being. J Gerontol A Biol Sci Med Sci 1998, 53: M385–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolf OT, Kudielka BM, Hellhammer DH, Hellhammer J, Kirschbaum C. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology 1998, 23: 617–29.PubMedCrossRefGoogle Scholar
  18. 18.
    Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, Nestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999, 84: 3896–902.PubMedGoogle Scholar
  19. 19.
    Van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effect of three months of DHEA supplementation. Psychoneuroendocrinology 2001, 26: 591–612.PubMedCrossRefGoogle Scholar
  20. 20.
    Ferrucci L, Bandinelli S, Benvenuti E, et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000, 48: 1618–25.PubMedGoogle Scholar
  21. 21.
    Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy cost of human physical activities. Med Sci Sports Exerc 1993, 25: 71–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995, 332: 556–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977, 1: 385–401.CrossRefGoogle Scholar
  24. 24.
    Guralnik JM, Fried LP, Simonsick EM, Kasper D, Lafferty ME. The women’s health and aging study: health and social characteristics of older women with disability. Bethesda, MD, National Institute on Aging. NIH Publication 1995, 95: 4009.Google Scholar
  25. 25.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12: 189–98.PubMedCrossRefGoogle Scholar
  26. 26.
    Launer LJ. Overview of incidence studies of dementia conducted in Europe. Neuroepidemiology 1992, 11(Suppl 1): 2–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Tombaugh TN, McIntyre NJ. The mini-mental state examination:a comprehensive review. J Am Geriatr Soc 1992, 40: 922–35.PubMedGoogle Scholar
  28. 28.
    Laurine E, Lafitte D, Grégoire C, et al. Specific binding of dehydroepiandrosterone to the N terminus of the microtubule-associated protein MAP 2. J Biol Chem 2003, 278: 29979–86.PubMedCrossRefGoogle Scholar
  29. 29.
    Bologa L, Sharma J, Roberts E. Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J Neurosci Res 1987, 17: 225–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Compagnone NA, Mellon SH. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci USA 1998, 95: 4678–83.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Roberts E, Bologa L, Flood JF, Smith GE. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res 1987, 406: 357–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Flood JF, Roberts E. Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res 1988, 448: 178–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Flood JF, Morley JE, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A 1992, 89: 1567–71.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Majewska MD, Demirgoren S, Spivak CE, London ED. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res 1990, 526: 143–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Demirgören S, Majewska MD, Spivak CE, London ED. Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor. Neuroscience 1991, 45: 127–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Monnet FP, Mahé V, Robel P, Baulieu EE. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 1995, 92: 3774–8.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Dong LY, Cheng ZX, Fu YM, et al. Neurosteroid dehydroepiandrosterone sulphate enhance a spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and sigma-1 receptors. Neuropharmacology 2007, 52: 966–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Steffensen SC, Jones MD, Hales K, Allison DW. Dehydroepiandrosterone sulfate and estrone sulfate reduce GABA-recurrent inhibition in the hippocampus via muscarinic acetylcholine receptors. Hippocampus 2006, 16: 1080–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Abadie JM, Porter JR, Wright BE, Browne ES, Svec F. The effect of discontinuing dehydroepiandrosterone supplementation on Zucker rat food intake and hypothalamic neurotransmitters. Int J Obes Relat Metab Disord 1995, 19: 480–8.PubMedGoogle Scholar
  40. 40.
    Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 1998, 95: 1852–7.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Bastianetto S, Ramassamy C, Poirier J, Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res 1999, 66: 35–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Kimonides VG, Spillantini MG, Sofroniew MV, Fawcett JW, Herbert J. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 1999, 89: 429–36.PubMedCrossRefGoogle Scholar
  43. 43.
    O’Brien JT, Schweitzer I, Ames D, Tuckwell V, Mastwyk M. Cortisol suppression by dexamethasone in the healthy elderly: effects of age, dexamethasone levels, and cognitive function. Biol Psychiatry 1994, 36: 389–94.PubMedCrossRefGoogle Scholar
  44. 44.
    Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990, 10: 2897–902.PubMedGoogle Scholar
  45. 45.
    Sapolsky RM. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp Gerontol 1999, 34: 721–32.PubMedCrossRefGoogle Scholar
  46. 46.
    Lupien SJ, Gaudreau S, Tchiteya BM, et al. Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. J Clin Endocrinol Metab 1997, 82: 2070–5.PubMedGoogle Scholar
  47. 47.
    Seeman TE, McEwen BS, Singer BH, et al. Increase in urinary cortisol excretion and memory declines: MacArthur studies on successful aging. J Clin Endocrinol Metab 1997, 82: 2458–65.PubMedGoogle Scholar
  48. 48.
    Carlson LE, Sherwin BB. Relationships among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women. Neurobiol Aging 1999, 20: 315–24.PubMedCrossRefGoogle Scholar
  49. 49.
    Ceresini G, Morganti S, Rebechi I, et al. Evaluation on the circadian profiles of serum dehydroepiandrosterone (DHEA), cortisol, and cortisol/DHEA molar ratio after a single oral administration of DHEA in elderly subjects. Metabolism 2000, 49: 548–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 2005, 288: E957–64.PubMedCrossRefGoogle Scholar
  51. 51.
    Maurice T, Su TP, Privat A. Sigma1 (sigma 1) receptor agonist and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998, 83: 413–28.PubMedCrossRefGoogle Scholar
  52. 52.
    Wolkowitz OM, Kramer JH, Reus VI, et al; DHEA-Alzheimer’s Disease Collaborative Research. DHEA treatment of Alzheimer’s disease. A randomized, double blind, placebo-controlled study. Neurology 2003, 60: 1071–6.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2009

Authors and Affiliations

  • G. Valenti
    • 1
  • L. Ferrucci
    • 2
  • F. Lauretani
    • 3
  • G. Ceresini
    • 1
  • S. Bandinelli
    • 4
  • M. Luci
    • 1
  • G. Ceda
    • 1
  • M. Maggio
    • 1
  • R. S. Schwartz
    • 5
  1. 1.Department of Internal Medicine and Medical Sciences, Section of GeriatricsUniversity of ParmaParmaItaly
  2. 2.Longitudinal Studies Section, Clinical Research BranchNational Institute on AgingBaltimoreUSA
  3. 3.Geriatric Rehabilitation DepartmentUniversity Hospital of ParmaParma
  4. 4.Geriatric UnitFlorenceItaly
  5. 5.Division of Geriatric MedicineUniversity of ColoradoDenverUSA

Personalised recommendations